Dcs
Astrocytoma
Gary Archer Ph.D.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Astrocytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Oliver Jonas | Phase 2 | BB |
Irinotecan Julie Krystal | Phase 2 | BB |
gsk1120212 Novartis Pharmaceuticals | Phase 4 | BB |
(+)-VINCRISTINE Novartis Pharmaceuticals | Phase 2 | BB |
Dabrafenib Novartis Pharmaceuticals | Phase 4 | BB |
View all 39 →
Same molecule, other indications
Dcs is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →